{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:24:12Z","timestamp":1780514652916,"version":"3.54.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.clml.2016.02.001","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T10:07:13Z","timestamp":1470737233000},"page":"S2-S5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S","title":["Blinatumomab: Bridging the Gap in Adult Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"16","author":[{"given":"Stephanie A.","family":"Folan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Rexwinkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Autry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.02.001_bib1","unstructured":"National Comprehensive Cancer Network. Acute Lymphoblastic Leukemia (Version 1.2015), 2015. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf. Accessed: September 2,\u00a02015."},{"key":"10.1016\/j.clml.2016.02.001_bib2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.02.001_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2016.02.001_bib4","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S1359-6446(05)03554-3","article-title":"BiTEs: bispecific antibody constructs with unique anti-tumor activity","volume":"10","author":"Wolf","year":"2005","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.clml.2016.02.001_bib5","series-title":"Blincyto(TM) [package insert]","year":"2014"},{"key":"10.1016\/j.clml.2016.02.001_bib6","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.yexcr.2011.03.010","article-title":"Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab","volume":"317","author":"Nagorsen","year":"2011","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.clml.2016.02.001_bib7","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1517\/14712598.2015.1041912","article-title":"Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies","volume":"15","author":"Rogala","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl 4","key":"10.1016\/j.clml.2016.02.001_bib8","first-page":"iv104","article-title":"Blinatumomab (CD3\/CD19 BiTE antibody) results in a high response rate in patients with relapsed non-Hodgkin lymphoma (NHL) including MCL and DLBCL","author":"Goebeler","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2016.02.001_bib9","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.001_bib10","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.001_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/asheducation-2010.1.7","article-title":"Minimal residual disease in acute lymphoblastic leukemia","volume":"2010","author":"Campana","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2016.02.001_bib13","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.001_bib14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.001_bib15","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.001_bib16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clml.2016.02.001_bib17","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1177\/1060028015588555","article-title":"Blinatumomab: a first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia","volume":"49","author":"Buie","year":"2015","journal-title":"Ann Pharmacother"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016000562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016000562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:18Z","timestamp":1761870558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016000562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":16,"alternative-id":["S2152265016000562"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.02.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blinatumomab: Bridging the Gap in Adult Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}